Stockscreener 앱 받기
1.97
3.14%
0.06
전일 마감가:
$1.91
열려 있는:
$1.9
하루 거래량:
435.03K
Relative Volume:
0.88
시가총액:
$274.89M
수익:
$79,600
순이익/손실:
$-48.26M
주가수익비율:
-4.0024
EPS:
-0.4922
순현금흐름:
$-28.24M
1주 성능:
-1.50%
1개월 성능:
-18.26%
6개월 성능:
+16.57%
1년 성능:
+18.67%
1일 변동 폭
$1.87
$1.98
1주일 범위
$1.86
$2.04
52주 변동 폭
$1.33
$2.61
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
명칭
Inhibikase Therapeutics Inc
전화
(302) 295-3800
주소
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Compare IKT vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.97 | 274.89M | 79,600 | -48.26M | -28.24M | -0.4922 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-06-10 | 개시 | Oppenheimer | Outperform |
| 2026-03-04 | 개시 | Ladenburg Thalmann | Buy |
| 2026-01-21 | 개시 | BofA Securities | Buy |
| 2025-12-26 | 개시 | H.C. Wainwright | Buy |
| 2025-12-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-02-12 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
모두보기
Inhibikase Therapeutics Inc 주식(IKT)의 최신 뉴스
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Two new hires receive options to buy up to 128,000 Inhibikase shares - Stock Titan
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Inhibikase advances IKT-001 in pivotal PAH Phase 3 - TipRanks
Inhibikase updates corporate presentation, highlights Phase 3 IKT-001 program and timelines - TradingView
Inhibikase (NASDAQ: IKT) tests PAH pill in pivotal global trial - Stock Titan
IKT News | INHIBIKASE THERAPEUTICS INC (NASDAQ:IKT) - ChartMill
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Inhibikase Therapeutics (IKT) Advances 3% as Shares Test Key Resistance ZoneMFI Overbought - dars.gov.et
Inhibikase Therapeutics (NASDAQ:IKT) Stock Price Down 4.1%What's Next? - MarketBeat
Inhibikase Therapeutics Appoints Deloitte & Touche LLP After Dismissing CohnReznick LLP as Auditor - Kalkine Media
Inhibikase (IKT) Chart: Adds 1.70% to Close at $2.39 in Latest Trading; Trading Range: the Supplied Trading Band Runs From $2.27 to $2.51 for the Current SessionFibonacci Extension - siam.in
Inhibikase (IKT) Chart: Adds 1.70% to Close at $2.39 in Latest Trading; Trading Range: the Supplied Trading Band Runs From $2.27 to $2.51 for the Current SessionDonchian Channel - vinanet.vn
Inhibikase (IKT) Q1 2026 Results: EPS Prints Above Forecast; Post-Earnings: Shares Finish 0.42% Higher at the CloseFree Cash Flow Trends - vinanet.vn
Inhibikase Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Inhibikase Therapeutics (IKT) Slips 1.5% as Shares Test Support at $2.25Shakeout Pattern - vinanet.vn
Inhibikase Loss Widens as Phase 3 PAH Trial Expands - MyChesCo
Inhibikase Therapeutics (IKT) Slips 1.5% as Shares Test Support at $2.25Call Dominated - dars.gov.et
Inhibikase Therapeutics (IKT) Holds Steady at $2.41 as Shares Consolidate Between $2.29 Support and $2.53 ResistanceReversal Setup Alerts - vinanet.vn
IKT Q1 2026 Earnings: Narrower Loss of $0.10 Per Share Beats Estimates as Pre-Revenue Biotech Holds SteadyEPS Surprise History - vinanet.vn
Perceptive group (IKT) discloses 6.9% Inhibikase stake through 10.3M warrant shares - Stock Titan
Nantahala reports 4.30% Inhibikase (IKT) stake across 5.81M shares - Stock Titan
IKT Q1 2026 Earnings: Narrower-than-Expected Loss Despite Modest Share PullbackNegative Surprise Momentum - vinanet.vn
Sands Capital group (NASDAQ: IKT) discloses 9.3% Inhibikase stake plus large warrants - Stock Titan
Inhibikase Therapeutics Faces Rising BIOSECURE, China Supply Chain and Trial Risks That Could Disrupt Growth - TipRanks
Oppenheimer Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Is Inhibikase Therapeutics Inc (IKT) Positioned for Growth After Reporting $0.11 Loss? GF Score: 36/100 - GuruFocus
LifeSci Capital Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Inhibikase grants $2.03 stock options to seven new hires - scanx.trade
Inhibikase Q2 EPS of $(0.11) meets analyst consensus estimates - scanx.trade
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity - Yahoo Finance
Inhibikase Therapeutics (IKT) Earnings Date and Reports 2026 $IKT - MarketBeat
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity - GlobeNewswire
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a shareEarnings Preview - TradingView
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Perceptive Advisors LLC Sells 3,106,568 Shares of Inhibikase Therapeutics, Inc. $IKT - MarketBeat
Inhibikase Therapeutics (IKT) Declines 4.4% as Stock Pressures Key $2.07 Support ZoneBreadth Thrust - dars.gov.et
Inhibikase Therapeutics (IKT) Slides 4.4% to $2.18 as Biotech Stock Presses Toward Key SupportEarly Entry Signals - vinanet.vn
Inhibikase Therapeutics, Inc. Revenue Breakdown – NASDAQ:IKT - TradingView
Inhibikase Wins FDA Orphan Status for PAH Drug Candidate - MyChesCo
18,030,000-share swap for warrant by Inhibikase Therapeutics, Inc. (IKT) - Stock Titan
H.C. Wainwright reiterates Inhibikase stock rating on FDA orphan drug status - Investing.com Canada
H.C. Wainwright reiterates Inhibikase stock rating on FDA orphan drug status - investing.com
Inhibikase Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline Progress Continues - dars.gov.et
IKT Q1 2026 Earnings: Narrower-than-Expected Loss per Share; Shares Slide 4.3%Profit Cycle Analysis - vinanet.vn
Inhibikase Therapeutics (IKT) Slips 1% as Shares Test Key Support at $2.21AI Trade Signals - vinanet.vn
Inhibikase Therapeutics Inc (IKT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Inhibikase Therapeutics Inc (IKT) Cash Flow - TradingKey
Inhibikase Therapeutics Inc (IKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Inhibikase Therapeutics Inc 주식 (IKT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sands Capital Life Sciences Pu | 10% Owner |
Nov 21 '25 |
Buy |
1.45 |
2,068,965 |
2,999,999 |
13,018,965 |
1.64%
0.29%
자본화:
|
볼륨(24시간):